GlassScriptPhysician profile
Logan Jay Shockley
NPI 1295374148
$4,007.69
in general payments reported to CMS, 2019-2025
40 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $804 · 2023: $471 · 2024: $1,274 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Education: $41.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.92 |
| Education | $41.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $417.79 | 2021-2025 | |
| Janssen Biotech, INC. | $391.74 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $340.51 | 2021-2025 | Enhertu, Tagrisso, Imfinzi |
| Incyte Corporation | $327.83 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Novocure Gmbh | $250.00 | 2022 | |
| Daiichi Sankyo INC. | $246.20 | 2023-2025 | Injectafer, Datroway, Enhertu |
| Regeneron Healthcare Solutions, INC. | $187.32 | 2021-2025 | Libtayo |
| Genentech USA, INC. | $171.05 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Celgene Corporation | $148.84 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $116.30 | 2021-2025 | Keytruda |
| Pfizer INC. | $106.60 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $105.99 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $101.74 | 2021-2024 | Xpovio |
| Array Biopharma INC | $80.20 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Exelixis INC. | $76.86 | 2024-2025 | Cabometyx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Shockley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.